412 related articles for article (PubMed ID: 24986517)
21. Targeting A3 and A2A adenosine receptors in the fight against cancer.
Merighi S; Battistello E; Giacomelli L; Varani K; Vincenzi F; Borea PA; Gessi S
Expert Opin Ther Targets; 2019 Aug; 23(8):669-678. PubMed ID: 31189400
[No Abstract] [Full Text] [Related]
22. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells.
Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP
Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191
[TBL] [Abstract][Full Text] [Related]
23. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
24. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
25. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.
Sierro SR; Donda A; Perret R; Guillaume P; Yagita H; Levy F; Romero P
Eur J Immunol; 2011 Aug; 41(8):2217-28. PubMed ID: 21538347
[TBL] [Abstract][Full Text] [Related]
26. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
27. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
28. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
31. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
[TBL] [Abstract][Full Text] [Related]
32. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
33. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
[TBL] [Abstract][Full Text] [Related]
34. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
Hatfield SM; Sitkovsky M
Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
[TBL] [Abstract][Full Text] [Related]
35. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
Yokouchi H; Yamazaki K; Chamoto K; Kikuchi E; Shinagawa N; Oizumi S; Hommura F; Nishimura T; Nishimura M
Cancer Sci; 2008 Feb; 99(2):361-7. PubMed ID: 18201271
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
37. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.
von Scheidt B; Leung PS; Yong MC; Zhang Y; Towne JE; Smyth MJ; Teng MW
Cancer Res; 2014 May; 74(9):2412-21. PubMed ID: 24556719
[TBL] [Abstract][Full Text] [Related]
38. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
39. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
40. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
